Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
13.08
+0.08 (0.62%)
At close: Jan 17, 2025, 4:00 PM
13.02
-0.06 (-0.46%)
After-hours: Jan 17, 2025, 5:05 PM EST
Syndax Pharmaceuticals Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for SNDX stock have an average target of 36.2, with a low estimate of 16 and a high estimate of 51. The average target predicts an increase of 176.76% from the current stock price of 13.08.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for SNDX stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 8 | 8 | 7 |
| Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 10 | 11 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Hold Maintains $18 → $16 | Hold | Maintains | $18 → $16 | +22.32% | Jan 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $51 | Strong Buy | Reiterates | $51 | +289.91% | Dec 10, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $33 → $38 | Buy | Maintains | $33 → $38 | +190.52% | Nov 21, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $37 → $45 | Strong Buy | Maintains | $37 → $45 | +244.04% | Nov 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $49 → $51 | Strong Buy | Maintains | $49 → $51 | +289.91% | Nov 18, 2024 |
Financial Forecast
Revenue This Year
86.43M
Revenue Next Year
98.66M
from 86.43M
Increased by 14.15%
EPS This Year
-2.89
from -2.98
EPS Next Year
-3.78
from -2.89
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 436.8M | 256.4M | 329.3M | |||
| Avg | 86.4M | 98.7M | 232.7M | |||
| Low | 15.7M | 45.7M | 140.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 196.7% | 233.7% | |||
| Avg | - | 14.1% | 135.8% | |||
| Low | - | -47.1% | 42.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.34 | -1.77 | -2.13 | |||
| Avg | -2.89 | -3.78 | -2.85 | |||
| Low | -3.82 | -4.70 | -3.43 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.